Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Angion
Companies To Watch: Angion Angion is developing a small molecule mimetic of the hepatocyte growth factor (HGF), which works to protect kidney and other organ cells from damage due to disease, physical injury, and indirect consequences of surgery and trauma.  Continue Reading...
  • Companies To Watch: Synlogic
    Companies To Watch: Synlogic

    Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.

  • GlycoMimetics Aiming At Tough Targets
    GlycoMimetics Aiming At Tough Targets

    An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.

  • Companies To Watch: Provention Bio
    Companies To Watch: Provention Bio

    This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.

  • Medicines360 On A Mission For Women
    Medicines360 On A Mission For Women

    Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.

  • Garo Armen And Audacity At Agenus
    Garo Armen And Audacity At Agenus

    Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.

  • Companies To Watch: Vyome Therapeutics
    Companies To Watch: Vyome Therapeutics

    Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.

  • Industry Explorers Blaze On: Howard Fillit
    Industry Explorers Blaze On: Howard Fillit

    An in-depth look at  the career and accomplishments of Howard Fillit, M.D., who has long led the exploration of Alzheimer’s disease outside and inside of the biopharma industry.

  • Companies To Watch: Azitra
    Companies To Watch: Azitra

    Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.

  • Companies-To-Watch 2018 Annual Roundup
    Companies-To-Watch 2018 Annual Roundup

    At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.

  • Three “Others” Of The New Oncology
    Three “Others” Of The New Oncology

    An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.

  • Companies To Watch: Synspira
    Companies To Watch: Synspira

    Synspira is developing glycopolymer drugs for infection, inflammation, and congestion in the lungs. According CEO Shenda Baker, “We would like to see more companies in this space. But we are also looking forward to leading the way.”

  • Is Biopharma Still Committed To Its Role In Public Health?
    Is Biopharma Still Committed To Its Role In Public Health?

    Biopharma executives in companies of all sizes share their views on whether the now dominant life sciences industry business model, with its focus on rare diseases affecting small patient populations, allows companies to meet their historical public-health obligation.

  • ARM Extends Its Reach
    ARM Extends Its Reach

    The ARM Foundation for Cell and Gene was launched in June, and it marks a new stage in development of the RM space as it moves from an early era or “promise” to one of fulfillment. Today, nearly 900 companies worldwide are developing RM therapies.

  • Companies To Watch: Athersys
    Companies To Watch: Athersys

    Athersys is mass-producing off-the-shelf stem cells for multiple conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.